View : 253 Download: 0

Effects of renin-angiotensin-aldosterone-system inhibitors on coronary atherosclerotic plaques: The PARADIGM registry

Title
Effects of renin-angiotensin-aldosterone-system inhibitors on coronary atherosclerotic plaques: The PARADIGM registry
Authors
WilliamsCurtisHanDongheeTakagiHidenobuFordyceChristopher B.SellersStephanieBlankePhilippLinFay Y.ShawLeslee J.LeeSang-EunAndreiniDanieleAl-MallahMouaz H.BudoffMatthew J.CademartiriFilippoChinnaiyanKavithaChoiJung HyunConteEdoardoMarquesHugode Araújo GonçalvesPedroGottliebIlanHadamitzkyMartinMaffeiEricaPontoneGianlucaShinSanghoonKimYong-JinByoung KwonChunEun JuSungJi MinVirmaniRenuSamadyHabibStonePeter H.BermanDaniel S.NarulaJagatBaxJeroen J.LeipsicJonathon A.ChangHyuk-Jae
Ewha Authors
신상훈
SCOPUS Author ID
신상훈scopusscopus
Issue Date
2023
Journal Title
Atherosclerosis
ISSN
0021-9150JCR Link
Citation
Atherosclerosis vol. 383
Keywords
ACE inhibitorCoronary CT angiographyPlaque morphologyPlaque progressionRAAS inhibitorStable coronary artery disease
Publisher
Elsevier Ireland Ltd
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Background and aims: Inhibition of Renin-Angiotensin-Aldosterone-System (RAAS) has been hypothesized to improve endothelial function and reduce plaque inflammation, however, their impact on the progression of coronary atherosclerosis is unclear. We aim to study the effects of RAAS inhibitor on plaque progression and composition assessed by serial coronary CT angiography (CCTA). Methods: We performed a prospective, multinational study consisting of a registry of patients without history of CAD, who underwent serial CCTAs. Patients using RAAS inhibitors were propensity matched to RAAS inhibitor naïve patients based on clinical and CCTA characteristics at baseline. Atherosclerotic plaques in CCTAs were quantitatively analyzed for percent atheroma volume (PAV) according to plaque composition. Interactions between RAAS inhibitor use and baseline PAV on plaque progression were assessed in the unmatched cohort using a multivariate linear regression model. Results: Of 1248 patients from the registry, 299 RAAS inhibitor taking patients were matched to 299 RAAS inhibitor naïve patients. Over a mean interval of 3.9 years, there was no significant difference in annual progression of total PAV between RAAS inhibitor naïve vs taking patients (0.75 vs 0.79%/year, p = 0.66). With interaction testing in the unmatched cohort, however, RAAS inhibitor use was significantly associated with lower non-calcified plaque progression (Beta coefficient −0.100, adjusted p = 0.038) with higher levels of baseline PAV. Conclusions: The use of RAAS inhibitors over a period of nearly 4 years did not significantly impact on total atherosclerotic plaque progression or various plaque components. However, interaction testing to assess the differential effect of RAAS inhibition based on baseline PAV suggested a significant decrease in progression of non-calcified plaque in patients with a higher burden of baseline atherosclerosis, which should be considered hypothesis generating. © 2023
DOI
10.1016/j.atherosclerosis.2023.117301
Appears in Collections:
의료원 > 의료원 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE